Almorexant Promotes Sleep and Exacerbates Cataplexy in a Murine Model of Narcolepsy | Zendy

Sarah Wurts Black | Zendy; Stephen R. Morairty | Zendy; Simon P. Fisher | Zendy; Tsui-Ming Chen | Zendy; Deepti R. Warrier | Zendy; Thomas S. Kilduff | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Almorexant Promotes Sleep and Exacerbates Cataplexy in a Murine Model of Narcolepsy

Author(s) -

Sarah Wurts Black,

Stephen R. Morairty,

Simon P. Fisher,

Tsui-Ming Chen,

Deepti R. Warrier,

Thomas S. Kilduff

Publication year - 2013

Publication title -

sleep

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.222

H-Index - 207

eISSN - 1550-9109

pISSN - 0161-8105

DOI - 10.5665/sleep.2442

Subject(s) - narcolepsy , cataplexy , orexin , rapid eye movement sleep , endocrinology , wakefulness , medicine , psychology , pharmacology , receptor , neuroscience , modafinil , neuropeptide , eye movement , electroencephalography

Humans with narcolepsy and orexin/ataxin-3 transgenic (TG) mice exhibit extensive, but incomplete, degeneration of hypo-cretin (Hcrt) neurons. Partial Hcrt cell loss also occurs in Parkinson disease and other neurologic conditions. Whether Hcrt antagonists such as almorexant (ALM) can exert an effect on the Hcrt that remains after Hcrt neurodegeneration has not yet been determined. The current study was designed to evaluate the hypnotic and cataplexy-inducing efficacy of a Hcrt antagonist in an animal model with low Hcrt tone and compare the ALM efficacy profile in the disease model to that produced in wild-type (WT) control animals.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research